Table 1.
Correlation of circRAPGEF5 expression with clinical characteristics
| Parameters | Patients (n=61) |
circRAPGEF5 | P value | |
|---|---|---|---|---|
| High expression (n=31) | Low expression (n=30) | |||
| Gender | 0.0151* | |||
| male | 29 | 10 (34.48%) | 19 (65.52%) | |
| female | 32 | 21 (65.63%) | 11 (34.37%) | |
| Age (years) | 0.5000 | |||
| <60 | 25 | 14 (56.00%) | 11 (44.00%) | |
| ≥60 | 36 | 17 (47.22%) | 19 (52.78%) | |
| T stage | 0.2381 | |||
| T1~2 | 57 | 28 (49.12%) | 29 (50.88%) | |
| T3~4 | 3 | 3 (100.00%) | 0 (0.00%) | |
| X# | 1 | 0 (0.00%) | 1 (100.00%) | |
| N stage | 0.0261* | |||
| N0 | 52 | 23 (44.23%) | 29 (55.77%) | |
| N1~3 | 9 | 8 (88.89%) | 1 (11.11%) | |
| M stage | >0.9999 | |||
| M0 | 60 | 30 (50.00%) | 30 (50.00%) | |
| M1 | 1 | 1 (100.00%) | 0 (0.00%) | |
| Tumor size (cm) | 0.8213 | |||
| ≤2 | 34 | 18 (52.94%) | 16 (47.06%) | |
| >2 | 26 | 13 (50.00%) | 13 (50.00%) | |
| X# | 1 | 0 (0.00%) | 1 (100.00%) | |
| CEA (μg/L) | 0.3305 | |||
| ≤5 | 44 | 24 (54.55%) | 20 (45.45%) | |
| >5 | 15 | 6 (40.00%) | 9 (60.00%) | |
| X# | 2 | 1 (50.00%) | 1 (50.00%) | |
The median expression level of circRAPGEF5 was used as the cut-off value. *: P < 0.05; #: “X” indicated that the tumor could not be evaluated or measured for the clinical characteristics, and these patients were not included in the statistical test.
Abbreviation: CEA, carcinoembryonic antigen.